<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001152</url>
  </required_header>
  <id_info>
    <org_study_id>IM047-013</org_study_id>
    <nct_id>NCT05001152</nct_id>
  </id_info>
  <brief_title>Taste Assessment of Ozanimod</brief_title>
  <official_title>An Open-Label Taste Assessment of Ozanimod in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the taste characteristics of ozanimod formulations,&#xD;
      alone and mixed, in order to develop a pediatric oral form of ozanimod.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 9, 2021</start_date>
  <completion_date type="Anticipated">October 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Taste evaluation - Aromatic identity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Measured using the Flavor Profile method of descriptive sensory analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste evaluation - Amplitude</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Measured using the Flavor Profile method of descriptive sensory analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste evaluation - Off-notes</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Measured using the Flavor Profile method of descriptive sensory analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste evaluation - Aftertaste</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Measured using the Flavor Profile method of descriptive sensory analysis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Ozanimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A maximum of 10 healthy adult participants (i.e., sensory panelists) will complete a maximum of 20 taste assessment days, with at least 4 panelists required to evaluate the taste characteristics of ozanimod on each taste assessment day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>Taste assessment</description>
    <arm_group_label>Ozanimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, between 25 and 80 years of age.&#xD;
&#xD;
          -  Participant is a qualified sensory panelist selected by Senopsys based on training and&#xD;
             experience&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has any history of any illness, medical condition, laboratory abnormality,&#xD;
             or psychiatric illness that might confound the results of the study or places the&#xD;
             panelist at unacceptable risk if he or she were to participate in the study.&#xD;
&#xD;
          -  Participant is a female that is pregnant, nursing, or planning to become pregnant&#xD;
             during the study.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Senopsys LLC</name>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ozanimod</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ozanimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

